Affinage

USP35

Ubiquitin carboxyl-terminal hydrolase 35 · UniProt Q9P2H5

Length
1018 aa
Mass
113.4 kDa
Annotated
2026-06-11
34 papers in source corpus 28 papers cited in narrative 27 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

USP35 is a deubiquitinating enzyme that operates through a substrate-stabilizing logic: by removing ubiquitin from a wide range of client proteins, it blocks their proteasomal turnover and thereby sustains the cellular programs those clients drive (PMID:29449677, PMID:29764563, PMID:29685892). In cell division it binds and deubiquitinates Aurora B, antagonizing APC/C-CDH1-mediated degradation to maintain Aurora B levels and faithful cytokinesis, and it similarly preserves the chromosomal passenger complex components survivin and Borealin (PMID:29449677, PMID:29764563, PMID:34438346). USP35 is a recurrent negative regulator of innate immune signaling, directly deubiquitinating and inactivating STING to suppress the STING-TBK1-IRF3 type I interferon axis and stripping K63-linked chains from MAVS to dampen antiviral signaling (PMID:32678307, PMID:40016186). Across cancer contexts it stabilizes effectors of survival, metabolism, and redox balance — anti-apoptotic IAP proteins including BIRC3, the glycolytic enzymes PKM2 and PFK-1, and the antioxidant master regulator NRF2 and iron exporter ferroportin to restrain ferroptosis (PMID:35022505, PMID:37173391, PMID:37594129, PMID:39714773, PMID:33931967). In the nucleus it acts as a transcriptional co-activator, stabilizing estrogen receptor α and enhancing its activity at estrogen response elements, with AKT phosphorylation at Ser613 driving USP35 nuclear translocation (PMID:34131114). USP35 exists as two alternatively spliced isoforms with distinct compartments and functions: a cytoplasmic/nuclear anti-apoptotic isoform and an ER/lipid-droplet integral membrane isoform whose deregulation provokes ER stress and cell death (PMID:29685892). Genetic suppression of the zebrafish ortholog rescues BBS4-dependent ciliopathy phenotypes by permitting proteasomal clearance of β-catenin and rhodopsin, defining USP35 as a brake on degradation of signaling effectors in vivo (PMID:31723061).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2015 Medium

    Established the first functional link between USP35 and a signaling pathway, showing it acts as a deubiquitinase that stabilizes a substrate to suppress NF-κB output.

    Evidence Co-IP, ubiquitination assay, and NF-κB reporter assay tracking ABIN-2 stabilization in TNFα-stimulated cells

    PMID:26348204

    Open questions at the time
    • Single lab without orthogonal substrate validation
    • ubiquitin linkage type on ABIN-2 not defined
    • physiological setting of NF-κB suppression not addressed
  2. 2018 High

    Defined USP35's role in mitosis and revealed that it counteracts a specific E3 ligase complex, framing it as a cell-cycle deubiquitinase rather than a generic DUB.

    Evidence Reciprocal Co-IP, ubiquitination assay, siRNA knockdown with H3-Ser10 and cytokinesis phenotypes, APC/C-CDH1 epistasis, and FoxM1 transcriptional regulation

    PMID:29449677 PMID:29764563

    Open questions at the time
    • Ubiquitin chain linkage removed from Aurora B not specified
    • structural basis of Aurora B recognition unknown
  3. 2018 High

    Resolved that USP35 is not a single functional entity but two splice isoforms with divergent localization and opposing consequences, explaining apparently conflicting phenotypes.

    Evidence Fluorescence imaging, subcellular fractionation, isoform-specific knockdown/overexpression, apoptosis and ER stress markers

    PMID:29685892

    Open questions at the time
    • Substrate repertoire of each isoform not mapped
    • mechanism by which ER/lipid-droplet isoform disrupts lipid homeostasis undefined
  4. 2019 Medium

    Provided in vivo, organism-level evidence that USP35 acts as a negative regulator of proteasomal clearance of signaling effectors, connecting its DUB activity to a developmental disease context.

    Evidence Genome-wide RNAi suppressor screen in BBS4-deficient zebrafish with convergent-extension, renal, and retinal phenotype scoring and β-catenin/rhodopsin clearance

    PMID:31723061

    Open questions at the time
    • Direct USP35 substrates in the cilium not identified
    • single lab
  5. 2020 High

    Identified USP35 as a brake on innate antiviral immunity by directly inactivating STING, and showed substrate engagement is phosphorylation-gated.

    Evidence Reciprocal Co-IP, ubiquitination assay, USP35 silencing with IRF3/TBK1 phosphorylation and IFN readouts, phosphorylation-dependent binding assay

    PMID:32678307

    Open questions at the time
    • Ubiquitin linkage type removed from STING not specified
    • kinase phosphorylating STING for USP35 binding not defined
  6. 2021 High

    Extended USP35's stabilizing activity to nuclear hormone signaling and connected it to upstream kinase control, showing AKT phosphorylation licenses nuclear function.

    Evidence Co-IP, ubiquitination assay, ChIP at estrogen response elements, AKT kinase assay with S613 mutagenesis, nuclear translocation imaging, in vivo validation

    PMID:34131114

    Open questions at the time
    • Whether co-activation requires catalytic activity at chromatin not resolved
    • interplay with ERα E3 ligases not mapped
  7. 2021 Medium

    Consolidated USP35 as a cytoprotective DUB across multiple cancer survival and ER-stress substrates, broadening the substrate set beyond Aurora B.

    Evidence DUB library screen, Co-IP, ubiquitination assays, activity-dead mutants, and functional ferroptosis/ER-stress/apoptosis readouts for survivin/CPC, ferroportin, and RRBP1

    PMID:33931967 PMID:34438346 PMID:34618999

    Open questions at the time
    • Each substrate validated in a single lab
    • shared recognition determinant across these substrates unknown
  8. 2023 Medium

    Positioned USP35 at the center of metabolic reprogramming and redox control in tumors, stabilizing glycolytic enzymes and the antioxidant regulator NRF2.

    Evidence Co-IP, ubiquitination assays, transcriptomics, and functional glycolysis/ferroptosis/apoptosis readouts across PKM2, NRF2, IAP family, FUCA1, and ABHD17C in multiple cancer models

    PMID:36864055 PMID:37173391 PMID:37594129 PMID:37993419

    Open questions at the time
    • Substrate selection mechanism unknown
    • isoform responsible for cytoplasmic versus ER substrate engagement not assigned
  9. 2024 Medium

    Showed USP35 expression is itself controlled post-transcriptionally and extended its stabilizing reach to transcriptional regulators, angiogenic and mitophagy factors.

    Evidence Co-IP, ubiquitination assays, FUS-USP35 mRNA stability assay, and functional readouts for BRD4/SLC7A11, VEGFA, PFK-1, and FUNDC1

    PMID:38953570 PMID:39406943 PMID:39714773 PMID:39820080

    Open questions at the time
    • Breadth of substrates raises question of specificity not addressed
    • single-lab validation per substrate
  10. 2025 Medium

    Expanded the immune-regulatory role to MAVS via linkage-specific deubiquitination and revealed non-canonical extracellular (exosomal) and structural-interaction dimensions of USP35.

    Evidence K63-specific ubiquitination assay and MAVS pathway readouts; exosome isolation and co-culture for STING/gastric cancer; HERC2 binding by X-ray crystallography (preprint)

    PMID:40016186 PMID:41372134

    Open questions at the time
    • STING gastric-cancer mechanism reported with limited methodological detail
    • functional consequence of HERC2 binding for USP35 not characterized
    • secretion mechanism for exosomal USP35 unknown
  11. 2026 Medium

    Refined the catalytic mechanism with site-specific deubiquitination on ID3 and revealed context-dependent outcomes, including DUB-driven autophagic (not proteasomal) degradation of MDM4.

    Evidence Co-IP, site-specific ubiquitination mutagenesis (ID3 K2/K30; MDM4), cycloheximide chase, PBMC/immune co-culture, kidney-specific knockout, and pharmacological inhibition (IU1)

    PMID:41486422 PMID:42002994 PMID:42185243

    Open questions at the time
    • How USP35 deubiquitination routes MDM4 to autophagy rather than stabilization is not mechanistically resolved
    • specificity of IU1 for USP35 in these contexts not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • What determines USP35 substrate selectivity among its many reported clients, and how the two isoforms partition this large substrate set across compartments, remains unresolved.
  • No structural model of substrate recognition
  • no systematic assignment of substrates to isoform 1 versus isoform 2
  • ubiquitin chain-type preference not defined across most substrates

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 8 GO:0016787 hydrolase activity 4 GO:0140110 transcription regulator activity 2
Localization
GO:0005634 nucleus 2 GO:0005783 endoplasmic reticulum 2 GO:0005811 lipid droplet 1 GO:0005829 cytosol 1
Pathway
R-HSA-168256 Immune System 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-1430728 Metabolism 3 R-HSA-1640170 Cell Cycle 2
Partners
AURKBBIRC3BRD4ESR1HERC2MAVSNFE2L2STING1
Complex memberships
chromosomal passenger complex

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 USP35 binds to and deubiquitinates Aurora B, inhibiting APC/C-CDH1-mediated proteasomal degradation of Aurora B to maintain its steady-state levels during mitosis. Loss of USP35 decreases phosphorylation of histone H3-Ser10 (an Aurora B substrate) and causes mitotic defects including cytokinesis failures. FoxM1 transcription factor promotes expression of USP35 during the cell cycle. Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, phosphorylation assay, FoxM1 ChIP/overexpression Nature communications High 29449677 29764563
2015 USP35 acts as a deubiquitinase that directly stabilizes ABIN-2 (TNFAIP3 interacting protein 2) by promoting its deubiquitination, thereby inhibiting TNFα-induced NF-κB activation. miR let-7a positively regulates USP35 expression. Co-immunoprecipitation, ubiquitination assay, NF-κB reporter assay, overexpression/knockdown, miRNA manipulation Oncotarget Medium 26348204
2018 USP35 has two alternatively spliced isoforms with distinct intracellular localizations and functions: isoform 1 localizes to the cytoplasm/nucleus and acts as an anti-apoptotic factor inhibiting staurosporine- and TRAIL-induced apoptosis; isoform 2 is an integral membrane protein of the endoplasmic reticulum and lipid droplets, and its deregulation causes ER stress and cell death, likely through disruption of lipid homeostasis. Fluorescence microscopy localization, isoform-specific knockdown/overexpression, apoptosis assays, ER stress markers, subcellular fractionation Journal of cell science High 29685892
2020 USP35 directly deubiquitinates STING to inactivate it, suppressing the STING-TBK1-IRF3 signaling pathway and downstream type I interferon production. Activated STING promotes its own binding to USP35 in a STING phosphorylation-dependent manner. Co-immunoprecipitation, ubiquitination assay, USP35 silencing with STING pathway readout (IRF3/TBK1 phosphorylation, IFN expression), phosphorylation-dependent binding assay Cell death and differentiation High 32678307
2021 USP35 directly interacts with ferroportin (FPN) and stabilizes it through deubiquitinase activity, preventing its proteasomal degradation. This maintains intracellular iron homeostasis and suppresses ferroptosis in lung cancer cells. Co-immunoprecipitation, ubiquitination assay, USP35 knockdown/overexpression with ferroptosis markers (lipid ROS, iron levels), xenograft model Clinical and translational medicine Medium 33931967
2021 USP35 directly interacts with and stabilizes RRBP1 (ribosome-binding protein 1, an ER membrane protein) by preventing proteasome-dependent degradation via deubiquitination. USP35-mediated RRBP1 stabilization alleviates ER stress-induced apoptosis in NSCLC cells. iTRAQ proteomics to identify interactome, Co-immunoprecipitation, ubiquitination assay, knockdown/overexpression with ER stress and apoptosis readouts Molecular oncology Medium 34618999
2021 USP35 stabilizes survivin protein in an enzymatic activity-dependent manner through direct interaction and deubiquitination. USP35 also regulates stability of other chromosomal passenger complex (CPC) components Aurora B and Borealin. The Drosophila homolog DUBAI similarly regulates Deterin (Drosophila survivin ortholog), indicating evolutionary conservation. DUB expression library screen (68 DUBs), Co-immunoprecipitation, ubiquitination assay, activity-dead mutant, Drosophila functional assay Biochemical and biophysical research communications Medium 34438346
2022 USP35 directly interacts with and stabilizes BIRC3 through deubiquitination of K48-linked polyubiquitin chains, protecting it from proteasomal degradation. USP35-mediated BIRC3 stabilization alleviates cisplatin-induced apoptosis in NSCLC cells. Co-immunoprecipitation, ubiquitination assay (K48-linkage specific), knockdown/overexpression with apoptosis readout Laboratory investigation Medium 35022505
2021 USP35 interacts with estrogen receptor α (ERα), deubiquitinates it, and enhances ERα protein stability. USP35 also interacts with ERα at estrogen response element-containing DNA regions to enhance ERα transcriptional activity. AKT phosphorylates USP35 at Serine613, which promotes USP35 nuclear translocation and ERα transcriptional activity. Co-immunoprecipitation, ubiquitination assay, ChIP, AKT kinase assay with site-specific mutagenesis (S613), nuclear translocation imaging, knockdown/overexpression in vitro and in vivo Cell death & disease High 34131114
2022 USP35 directly deubiquitinates and stabilizes BRPF1 protein. Accumulated BRPF1 binds to the SREBP2 promoter to activate SREBP2 transcriptional activity, promoting expression of mevalonate (MVA) metabolism genes in prostate cancer cells. Co-immunoprecipitation, ubiquitination assay, ChIP (BRPF1 on SREBP2 promoter), knockdown/overexpression with mevalonate pathway readout, in vivo xenograft Cell death discovery Medium 36357379
2023 USP35 stabilizes multiple IAP family members (including BIRC3 and others) in an enzymatic activity-dependent manner, protecting renal clear cell carcinoma cells from apoptosis. USP35 also catalyzes deubiquitylation of NRF2, maintaining NRF2 protein levels and protecting cells from ferroptosis. Biochemical characterization (ubiquitination assay, activity-dependent stabilization), transcriptomic analysis of NRF2 downstream targets, knockdown with apoptosis and ferroptosis readouts, xenograft Cell death and differentiation Medium 37173391
2023 USP35 directly deubiquitinates and stabilizes PKM2 (pyruvate kinase M2 isoform), protecting it from ubiquitin-mediated degradation and maintaining the Warburg effect (aerobic glycolysis) in hepatocellular carcinoma cells. Co-immunoprecipitation, ubiquitination assay, Western blot of PKM2 stability, knockdown with glycolysis readout International journal of oncology Medium 37594129
2023 USP35 directly interacts with and deubiquitinates FUCA1 (α-L-fucosidase 1), stabilizing it from proteasomal degradation. The USP35-FUCA1 axis promotes upregulation of NER components (XPC, XPA, ERCC1), providing a mechanistic basis for platinum resistance in colorectal cancer. Co-IP followed by mass spectrometry, Co-IP validation, ubiquitination assay, knockdown/overexpression with NER component readout, in vitro and in vivo functional assays Oncogenesis Medium 36864055
2023 USP35 interacts with and stabilizes ABHD17C by inhibiting its ubiquitin-proteasome-mediated degradation, leading to activation of the PI3K/AKT signaling pathway in hepatocellular carcinoma cells. Co-immunoprecipitation, ubiquitination assay, USP35 knockdown with PI3K/AKT pathway readout, ABHD17C rescue experiment, xenograft Cell death discovery Medium 37993419
2019 Genetic suppression or ablation of usp35 (zebrafish ortholog) ameliorates ciliopathy defects caused by BBS4 loss, including impaired convergent extension, renal tubule convolution, and retinal degeneration, with concomitant clearance of β-catenin and rhodopsin. This places USP35 as a negative regulator of proteasome-dependent degradation of ciliopathy-relevant signaling effectors. Genome-wide RNAi suppressor screen (in BBS4-deficient background), transient and stable zebrafish genetic models, convergent extension assay, renal and retinal phenotype scoring JCI insight Medium 31723061
2024 USP35 deubiquitinates and stabilizes BRD4. BRD4 then mediates USP35-induced upregulation of SLC7A11, inhibiting ferroptosis and promoting growth of ER+ breast cancer cells. BRD4 inhibitor (+)-JQ-1 inhibits USP35-enhanced tumorigenesis in vivo. Co-immunoprecipitation, ubiquitination assay, BRD4 knockdown/inhibitor rescue, SLC7A11 expression readout, ferroptosis markers, in vivo xenograft with JQ-1 treatment Communications biology Medium 39820080
2024 USP35 interacts with and deubiquitinates VEGFA, stabilizing VEGFA protein levels. FUS RNA-binding protein interacts with USP35 mRNA to promote its mRNA stability, thereby positively regulating VEGFA expression in NSCLC cells. Co-IP assay, ubiquitination assay, FUS knockdown/overexpression with USP35 mRNA stability readout, functional angiogenesis assay, in vivo xenograft General physiology and biophysics Medium 38953570
2024 USP35 directly interacts with and stabilizes PFK-1 (phosphofructokinase-1) via deubiquitination, reducing its ubiquitin-mediated degradation. USP35-mediated PFK-1 stabilization promotes glycolysis and cell proliferation in breast cancer cells. Co-immunoprecipitation, ubiquitination assay, Seahorse metabolic assay (ECAR/OCR), knockdown/overexpression with glycolysis readout, in vivo xenograft American journal of physiology. Cell physiology Medium 39714773
2024 USP35 interacts with and stabilizes FUNDC1 (a mitophagy receptor) by deubiquitination. USP35-mediated FUNDC1 stabilization enhances autophagy/mitophagy and reduces mitochondrial ROS in OGD/R-injured neuronal cells. Co-immunoprecipitation, ubiquitination assay, USP35 overexpression with FUNDC1 protein stability and autophagy readout, FUNDC1 knockdown rescue experiment Communications biology Medium 39406943
2024 USP35 deubiquitinates and stabilizes NRF2 in esophageal cancer cells, maintaining NRF2 protein stability through direct interaction and enzymatic deubiquitination. Co-immunoprecipitation, ubiquitination assay, USP35 knockdown with NRF2 protein level readout Open life sciences Low 39156988
2025 USP35 interacts with MAVS and removes K63-linked polyubiquitin chains from MAVS, thereby inhibiting viral-induced MAVS-TBK1-IRF3 pathway activation and downstream inflammatory gene expression. Co-immunoprecipitation, K63-linkage-specific ubiquitination assay, USP35 depletion with MAVS pathway readout (TBK1/IRF3 activation, cytokine expression), in vivo anti-tumor immunity assay Cell death & disease Medium 40016186
2025 USP35 directly deubiquitinates and stabilizes STING in gastric cancer cells, activating the HIF-1α/FAK pathway to promote energy metabolism reprogramming and adhesion to peritoneal mesothelial cells. USP35 is also secreted via exosomes from gastric cancer cells and promotes mesothelial-mesenchymal transformation (MMT) of peritoneal mesothelial cells. Co-immunoprecipitation, ubiquitination assay, pathway readout (HIF-1α/FAK), exosome isolation and co-culture functional assay Cell death & disease Low 41372134
2025 USP35 interacts with and stabilizes GASC1 (gene amplified in squamous cell carcinoma 1) by reducing GASC1 ubiquitination, leading to upregulation of ROCK2 expression and promotion of HCC cell proliferation. Co-immunoprecipitation, ubiquitination assay, knockdown/overexpression with ROCK2 expression and proliferation readout Translational oncology Low 40424935
2026 USP35 deubiquitinates and stabilizes ID3 at its N-terminal lysine residues K2 and K30, enhancing ID3 transcriptional activity and resulting in elevated PD-L1 expression in colorectal cancer, facilitating immune escape. The USP35 inhibitor IU1 promotes ID3 ubiquitination and reduces PD-L1 expression. Co-immunoprecipitation, ubiquitination assay with site-specific mutagenesis (K2, K30), PD-L1 expression readout, pharmacological inhibition with IU1, immune co-culture assay Advanced science Medium 41486422
2026 USP35 directly deubiquitinates and stabilizes CDCA8 (a cell cycle regulator) and also deubiquitinates PD-L1 to prevent its proteasomal degradation, thereby promoting NSCLC cell proliferation/invasion and immune evasion respectively. Co-immunoprecipitation, ubiquitination assay, cycloheximide chase, PBMC co-culture cytotoxicity assay, knockdown with proliferation and immune readouts Combinatorial chemistry & high throughput screening Medium 42002994
2026 USP35 deubiquitinates MDM4, leading to its autophagic degradation (rather than proteasomal stabilization), which activates the P53 signaling pathway and mediates endothelial ferroptosis in cisplatin-induced acute kidney injury. Kidney-specific USP35 knockout reduces AKI and endothelial ferroptosis. Transcriptomic and single-cell analyses, renal epithelial cell and animal models, kidney-specific USP35 knockout, ubiquitination assay, P53 pathway readout, ferroptosis markers Cell death discovery Medium 42185243
2025 HERC2 binds to USP35 via a conserved 'DxDKDxD' motif recognized by the RLD2 domain of HERC2, identifying USP35 as a HERC2-interacting protein relevant to brain development. Quantitative binding assays, X-ray crystallography, sequence conservation analysis bioRxiv (preprint)preprint Low bio_10.1101_2025.09.16.670041

Source papers

Stage 0 corpus · 34 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2021 Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin. Clinical and translational medicine 144 33931967
2020 Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer. Cell death and differentiation 77 32678307
2018 USP35 regulates mitotic progression by modulating the stability of Aurora B. Nature communications 45 29449677
2015 USP35 activated by miR let-7a inhibits cell proliferation and NF-κB activation through stabilization of ABIN-2. Oncotarget 34 26348204
2022 Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced apoptosis by stabilizing BIRC3 in non-small cell lung cancer. Laboratory investigation; a journal of technical methods and pathology 33 35022505
2021 USP35 mitigates endoplasmic reticulum stress-induced apoptosis by stabilizing RRBP1 in non-small cell lung cancer. Molecular oncology 33 34618999
2023 The deubiquitylating enzyme USP35 restricts regulated cell death to promote survival of renal clear cell carcinoma. Cell death and differentiation 25 37173391
2021 USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α. Cell death & disease 23 34131114
2023 USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination‑mediated degradation. International journal of oncology 22 37594129
2018 Expansion of DUB functionality generated by alternative isoforms - USP35, a case study. Journal of cell science 22 29685892
2023 USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer. Oncogenesis 15 36864055
2023 USP35 promotes HCC development by stabilizing ABHD17C and activating the PI3K/AKT signaling pathway. Cell death discovery 15 37993419
2022 USP35 is a Potential Immunosuppressive Factor in Skin Cutaneous Melanoma. Journal of inflammation research 12 35637872
2022 Deubiquitinase USP35 stabilizes BRPF1 to activate mevalonate (MVA) metabolism during prostate tumorigenesis. Cell death discovery 12 36357379
2025 USP35 promotes the growth of ER positive breast cancer by inhibiting ferroptosis via BRD4-SLC7A11 axis. Communications biology 10 39820080
2019 Genome-wide suppressor screen identifies USP35/USP38 as therapeutic candidates for ciliopathies. JCI insight 9 31723061
2021 Regulation of survivin protein stability by USP35 is evolutionarily conserved. Biochemical and biophysical research communications 7 34438346
2024 USP35 promotes breast cancer progression by regulating PFK-1 ubiquitination to mediate glycolysis. American journal of physiology. Cell physiology 6 39714773
2018 Deubiquitinase USP35 as a novel mitotic regulator via maintenance of Aurora B stability. BMB reports 5 29764563
2024 FUS-stabilized USP35 promotes growth, invasion and angiogenesis in NSCLC through deubiquitinating VEGFA. General physiology and biophysics 4 38953570
2024 Overexpression of USP35 enhances the protective effect of hUC-MSCs and their extracellular vesicles in oxygen-glucose deprivation/reperfusion-induced SH-SY5Y cells via stabilizing FUNDC1. Communications biology 4 39406943
2024 The USP35-CXCR3 Axis plays an oncogenic role in JeKo-1 mantle cell lymphoma cells. Integrative biology : quantitative biosciences from nano to macro 3 39591978
2025 Deubiquitination enzyme USP35 negatively regulates MAVS signaling to inhibit anti-tumor immunity. Cell death & disease 2 40016186
2025 Oncogenic and immunological functions of USP35 in pan-cancer and its potential as a biomarker in kidney clear cell carcinoma. BMC cancer 2 40188027
2025 USP35 promotes hepatocellular carcinoma proliferation through GASC1-mediated ROCK2 upregulation. Translational oncology 2 40424935
2024 The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein. Open life sciences 1 39156988
2026 USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 41486422
2026 Glycine Alleviates H2O2-Induced Ferroptosis in Mouse Hippocampal Neuron HT22 Cells via the GlyRɑ1/USP35/FPN1 Signaling Pathway. Molecular neurobiology 0 41903061
2026 USP35 Acts as a Dual Stabilizer of CDCA8 and PD-L1 to Coordinate the Progression and Immune Evasion in Non-Small Cell Lung Cancer. Combinatorial chemistry & high throughput screening 0 42002994
2026 The deubiquitinase USP35: from an oncogenic hub to a therapeutic target in human cancers. Frontiers in oncology 0 42180131
2026 Deubiquitinase USP35 regulates MDM4 degradation to promote endothelial ferroptosis and renal injury progression. Cell death discovery 0 42185243
2025 Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35. BMC cancer 0 41044693
2025 Comprehensive pan-cancer analysis of USP35 and validation of its role in gastric cancer. Human genomics 0 41225657
2025 De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming. Cell death & disease 0 41372134

Missed literature

Know a paper Affinage missed for USP35? Flag it for the maintainers and the community.

No submissions yet.